TMA-6 - PsychonautWiki
Summary sheet: TMA-6
TMA-6
TMA-6.svg
Chemical Nomenclature
Common names TMA-6
Substitutive name 2,4,6-trimethoxyamphetamine
Systematic name 1-(2,4,6-trimethoxyphenyl)propan-2-amine
Class Membership
Psychoactive class Psychedelic / Stimulant
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 10 - 20 mg
Common 20 - 35 mg
Strong 35 - 50 mg
Heavy 50 mg +
Duration
Total 10 - 16 hours
Onset 30 - 90 minutes
Come up 1.5 - 3 hours
Peak 5 - 8 hours
Offset 3 - 5 hours
After effects 6 - 18 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
SNRIs
MAOIs
Serotonin releasers
SSRIs
5-HTP


2,4,6-Trimethoxyamphetamine (also known as TMA-6) is a lesser-known psychedelic substance of the amphetamine class. It has been reported to produce a complex mixture of stimulant, hallucinogenic and entactogenic effects that distinguish it from other psychedelic phenethylamine derivatives like the 2C-x or DOx series.

TMA-6 has no history of human usage prior to the 1991 publication of its synthesis and pharmacology in the book PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander Shulgin, who called it "one of the most rewarding and pleasurable of the methoxylated amphetamines".[1] Since then it has been regarded as a novelty in the psychedelics community and is made available for sale only rarely by clandestine laboratory operations.

In terms of its subjective effects, it is known for its lack of classic psychedelic visuals compared to other hallucinogenic phenethylamines and is known instead for its unique stimulating body-high and intoxicating headspace.

Anecdotal reports suggest that TMA-6 is unpredictable and dose-sensitive substance that can produce uncomfortable amounts of body load, nausea, overstimulation, and inconsistencies between experiences.

In modern times, TMA-6 is used rarely as a recreational drug and a putative entheogen. It has no documentation of being sold on the streets[citation needed] and is almost exclusively obtainable as an obscure gray area research chemical through the use of online vendors.

Chemistry

TMA-6, or 2,4,6-trimethoxyamphetamine, is a molecule of the substituted amphetamine class. Amphetamines are substituted phenethylamines, being comprised of a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα. TMA-6 contains methoxy functional groups CH3O- attached to carbons R2 and R4 and R6 of the amphetamine backbone.[1]

Pharmacology

 

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

TMA-6's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

 
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Cognitive effects
 

Visual effects
 

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational TMA-6 use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because TMA-6 has very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried TMA-6 suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Tolerance and addiction potential

Though largely unstudied TMA-6 is largely considered to be not habit-forming and the desire to use it can actually decrease with consumption. It is most often self-regulating.

Tolerance to the effects of TMA-6 are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). TMA-6 presents cross-tolerance with all psychedelics, meaning that after the consumption of TMA-6 all psychedelics and stimulants will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany: TMA-6 is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.[4][5] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[6]
  • Switzerland: TMA-6 is not specifically named, although it can be considered an ether analog of an ether analog of PMA, which would make it illegal according to Buchstabe C.[7]
  • Turkey: TMA-6 is a classed as drug and is illegal to possess, produce, supply, or import.[8] [9]

See also

External links

References

  1. 1.0 1.1 Erowid Online Books : “PIHKAL” - #162 TMA-6 
  2. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., Abdollahi, M. (June 2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  3. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  4. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019. 
  5. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  7. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  8. Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü 
  9. https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf